Your browser doesn't support javascript.
loading
Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST).
O'Connor, C M; Gattis, W A; Uretsky, B F; Adams, K F; McNulty, S E; Grossman, S H; McKenna, W J; Zannad, F; Swedberg, K; Gheorghiade, M; Califf, R M.
Affiliation
  • O'Connor CM; Duke University Medical Center, Durham, NC 27710, USA. oconn002@mc.duke.edu
Am Heart J ; 138(1 Pt 1): 78-86, 1999 Jul.
Article in En | MEDLINE | ID: mdl-10385768
Subject(s)
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Dobutamine / Heart Failure Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 1999 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos
Search on Google
Add to My VHL
Print
XML
PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Cardiotonic Agents / Dobutamine / Heart Failure Type of study: Clinical_trials / Etiology_studies / Risk_factors_studies Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 1999 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos